The invention concerns the use of an H1- and/or H2-histamine receptor antagonist for the reduction of intracranial pressure (ICP) in particular for the prevention and treatment of elevated intracranial pressure and/or secondary ischaemia in particular caused by brain injury more in particular caused by traumatic (TBI) and non-traumatic brain injury. In particular the histamine antagonist is selected from the group of acrivastine alimemazine antazoline astemizole azatadine azelastine brompheniram...

The invention relates to a pharmaceutical composition of a tablet-type controlled-release preparation for treating all types of vertigo. The invention also relates to a pharmaceutical composition containing cinnarizine and dimenhydrinate in which the release of the active ingredients is controlled. The pharmaceutical composition also contains binding agents controlled-release agents and fillers.

The invention relates to pharmaceutical dosage forms that are suitable for improving the release of cinnarizine and thus the bioavailability thereof, even if there is a low amount of liquid in the gastrointestinal tract. The invention further relates to a production method for such dosage forms and to uses of such dosage forms. One aspect of the invention also relates to a particle matrix that substantially contributes to the effect according to the invention. The result according to the inventi...

The invention relates to a production method for dosage forms. The production method makes dosage forms accessible that help even active ingredients that are poorly soluble to be highly bioavailable when taken orally. Another important advantage of the method is that the dosage forms produced in such a manner have good storage stability. The dosage forms produced in such a manner comprise several subunits. The invention further relates to the dosage forms and to uses of the dosage forms. In part...

The invention concerns the use of an H1- and/or H2-histamine receptor antagonist for the reduction of intracranial pressure (ICP) in particular for the prevention and treatment of elevated intracranial pressure and/or secondary ischaemia in particular caused by brain injury more in particular caused by traumatic (TBI) and non-traumatic brain injury. In particular the histamine antagonist is selected from the group of acrivastine alimemazine antazoline astemizole azatadine azelastine brompheniram...